SOUTH SAN FRANCISCO, Calif.,
Aug. 1, 2018 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today
announced that it will report its second quarter 2018 financial
results after market close on Wednesday,
August 8, 2018. Rigel senior management will follow the
announcement with a live conference call and webcast at
5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial
results and give a company update.
Participants can access the live conference call by dialing
(855) 892-1489 (domestic) or (720) 634-2939 (international) and
using the Conference ID number 8192317. The conference call
will also be webcast live and can be accessed from Rigel's website
at www.rigel.com. The webcast will be archived and available
for replay for 30 days after the call via the Rigel website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen
tyrosine kinase (SYK) inhibitor, for the treatment of adult
patients with chronic immune thrombocytopenia who have had an
insufficient response to a previous treatment. Rigel's current
clinical programs include Phase 2 studies of fostamatinib in
autoimmune hemolytic anemia and IgA nephropathy. In addition, Rigel
has product candidates in development with partners BerGenBio
AS, Daiichi Sankyo, and Aclaris Therapeutics.
Please see www.TAVALISSE.com for the
full Prescribing Information.
IR Contact: Dean Schorno
Phone: 650.624.1284
Email: ir@rigel.com
Media Contact: Jessica Daitch
Phone: 917.816.6712
Email: jessica.daitch@syneoshealth.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2018-financial-results-300689788.html
SOURCE Rigel Pharmaceuticals, Inc.